Tetraphase Pharmaceuticals to Present at Upcoming Investor Conferences
- Stifel 2017 Healthcare Conference on
Tuesday, November 14, 2017at 8:00 a.m. Eastern Timeat the Lotte New York Palace Hotelin New York City
- PiperJaffray 29th Annual Healthcare Conference on
Wednesday, November 29, 2017at 9:30 a.m. Eastern Timeat the Lotte New York Palace Hotelin New York City
Live audio webcasts of the presentations will be available on the company’s website at http://ir.tphase.com/events.cfm. Archived presentations will be available for 30 days.
About Tetraphase Pharmaceuticals, Inc.
Tetraphase is a clinical-stage biopharmaceutical company using its proprietary chemistry technology to create novel antibiotics for serious and life-threatening bacterial infections, including those caused by many of the multidrug-resistant (MDR) bacteria highlighted as urgent public health threats by the CDC. Tetraphase has created more than 3,000 novel tetracycline analogs using its proprietary technology platform. Tetraphase's pipeline includes three antibiotic clinical candidates: eravacycline, which is in phase 3 clinical trials, and TP-271 and TP-6076, which are in phase 1 clinical trials. Please visit www.tphase.com for more company information.
Source: Tetraphase Pharmaceuticals, Inc.